Dr. Reddy's Launches First Generic Olopatadine Eye Drops in U.S. Market
Dr. Reddy's has successfully launched the first generic version of Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% in the U.S. market, becoming the pioneer in offering a generic equivalent to Extra-Strength Pataday Once Daily Relief. The FDA-approved over-the-counter eye drop provides temporary relief from itchy eyes caused by allergens and expands the company's existing ophthalmology portfolio that includes 0.1% and 0.2% strength versions.
*this image is generated using AI for illustrative purposes only.
Dr. Reddy's has achieved a significant milestone by launching the first generic version of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S. market. The over-the-counter (OTC) product has received approval from the U.S. Food and Drug Administration (USFDA) and represents a major expansion of the company's ophthalmology portfolio.
Product Launch Details
The antihistamine eye drop is indicated for temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander. The following table summarizes the key product specifications:
| Parameter: | Details |
|---|---|
| Product Name: | Olopatadine Hydrochloride Ophthalmic Solution USP |
| Concentration: | 0.7% |
| Market Status: | First Generic Version |
| Product Type: | Over-the-Counter (OTC) |
| Package Size: | 2.5 mL bottle |
| Reference Brand: | Extra-Strength Pataday® Once Daily Relief |
Market Performance and Strategic Impact
The launch holds significant commercial potential, with the Pataday® brand generating U.S. sales of approximately $69.90 million according to company regulatory filings. This first-to-market opportunity demonstrates Dr. Reddy's regulatory expertise and manufacturing capabilities in specialized dosage forms.
"This launch adds to our current portfolio in the OTC eye-care space which includes Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% strengths," explained Milan Kalawadia, CEO, North America Generics, Dr. Reddy's Laboratories, Inc. "The first-to-market launch is a testament to our deep capabilities in bringing store-brand equivalents of OTC brands in the U.S. market."
Portfolio Expansion and Stock Performance
This product launch strengthens Dr. Reddy's position in the competitive U.S. generics market, particularly in the specialty ophthalmology segment. The company's existing OTC eye-care portfolio already includes multiple strengths of Olopatadine Hydrochloride Ophthalmic Solution, and this addition further solidifies its presence in the eye-care market.
The market responded positively to the announcement, with shares ending marginally higher at ₹1,191.50 apiece, gaining 0.02%. The successful launch reflects Dr. Reddy's ongoing commitment to expanding its product portfolio in key therapeutic areas and leveraging its research and development capabilities to bring important generic medications to market.
| Market Data: | Details |
|---|---|
| Share Price: | ₹1,191.50 |
| Daily Change: | +0.02% |
| Pataday Brand Sales: | $69.90 million |
The company continues to deepen its collaboration with retail customers through store-brand portfolio additions, positioning itself for continued growth in the competitive U.S. generics market.
19
